Erdafitinib
Balversa · FGFR inhibitor
Hyperphosphatemia is an on-target class effect.
Pemazyre · Pemi
FGFR inhibitor · approved 2020 · 9 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
An FGFR1/2/3 inhibitor for cholangiocarcinoma — hyperphosphatemia is its near-universal class signature.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Hyperphosphatemia is the most common adverse event in the pivotal FIGHT-202 trial, affecting roughly 60% of patients (any grade), with low rates of severe events; it is on-target and managed with monitoring, diet, and binders.Source: Abou-Alfa et al., Lancet Oncol 2020
Early — within the first cycles.
Distilled from: “Early — within the first cycles.”
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Selective FGFR1/2/3 inhibitor blocking oncogenic FGFR signaling; approved for FGFR2-fusion/rearrangement-positive cholangiocarcinoma.
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Class-level context for the major non-renal toxicities of the FGFR inhibitor class.
Ophthalmic
Keratopathy, uveitis, retinopathy
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
6 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Jun 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
Reduce the recommended dosage of PEMAZYRE for patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m 2 , estimated by MDRD equation) [see Dosage and Administration ( 2.5 ) and Clinical Pharmacology ( 12.3 )] . No dosage adjustment is recommended for patients with mild or moderate renal impairment (eGFR 30 to 89 mL/min/1.73 m 2 ). No dosage adjustment is recommended for patients with end-stage renal disease (eGFR < 15 mL/min/1.73 m 2 ) who are receiving intermittent hemodialysis [ see Clinical Pharmacology ( 12.3 )] .
Kidney rows of the label's dosage tables
From the PEMAZYRE label (Jun 2026) · DailyMed
No row of this label's 2 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 853 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
150 of 853 reports
Reported with hospitalization
205 of 853 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Pemigatinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Balversa · FGFR inhibitor
Hyperphosphatemia is an on-target class effect.
Lytgobi · FGFR inhibitor
Hyperphosphatemia, class effect.
Truseltiq · FGFR inhibitor
Hyperphosphatemia — on-target FGFR class effect; nephrocalcinosis risk.
Xgeva · Anti-RANKL antibody
Severe hypocalcemia in low GFR; not directly nephrotoxic.
Portrazza · Anti-EGFR antibody
Severe hypomagnesemia, class effect.
Aqupla · Platinum agent
Second-gen platinum with reduced renal toxicity vs cisplatin.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.